Comment: Fundamentals and Innovation in Antibiotic Trials

References

• AIDAC (2012), Capital Reporting Company. Anti-Infective Drugs Advisory Committee (AIDAC) Meeting 29 November 2012, available at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM340465.pdf
   Google Scholar
• Couzin-Frankel, J. (2015), “Clinical Trials Get Practical,” Science, 348, 382.
   Google Scholar
• Cox, E., Borio, L., and Temple, R. (2014), “Evaluating Ebola Therapies —-The Case for RCTs,” New England Journal of Medicine, 371, 2350–2351.
   Google Scholar
• D’Agostino R.B, Massaro J.M, and Sullivan, LM.. (2003), “Non-Inferiority Trials: Design Concepts and Issues—The Encounters of Academic Consultants in Statistics,” Statistics in Medicine, 22, 169–86.
   Google Scholar
• Dodd, L.E., Proschan, M.A., Neuhaus, J., Koopmeiners, J., Neaton, J., Beigel, J.D., Barrett, K., Lane, H.C., and Davey, R.T. (2015), “Design of a Randomized Controlled-Trial for Ebola Virus Disease Medical Countermeasures: The Ebola MCM Study,” unpublished manuscript.
   Google Scholar
• Evans, S.R. (2009), “Noninferiority Clinical Trials,” Chance, 22, 53–8.
   Google Scholar
• ——— (2010), “Estudos Clinicos de Nao-Inferioridade,” Revista Brasileira de Medicina, 67, 7.
   Google Scholar
• Evans, S.R., Rubin, D., Follmann, D., Pennello, G., Huskins, W.C., Powers, J.H., Schoenfeld, D., Chuang-Stein, C., Cosgrove, S.E., Fowler Jr., V.G., Lautenbach, E., and Chambers, H.F. (2015), “Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR),” CID, 61, 800–806.
   Google Scholar
• FDA (2013), “Guidance for Industry Acute Skin and Skin Structure Infections: Developing Drugs for Treatment,” available at http://www.fda.gov/downloads/Drugs/Guidances/ucm071185.pdf
   Google Scholar
• Falagas M.E., and Kasiakoum, S.K. (2005), “Colistin: The Revival of Polymyxins for the Management of Multidrug-Resistant Gram-negative Bacterial Infections,” Clinical Infectious Diseases, 40, 1333–1341.
   Google Scholar
• Falagas, M.E., Tansarli, G.S., Karageorgopoulos, D.E., and Vardakas, K.Z. (2014), “Deaths Attributable to Carbapenem-Resistant Enterobacteriaceae Infections,” Emerging Infectious Diseases, 20, 1170--1175.
   Google Scholar
• Flacco, M.E., Manzolia, L., Boccia, S., Capasso, L., Aleksovska, K., Rosso, A., Scaioli, G., De Vitoe, C., Siliquinif, R., Villarie, P., and Ioannidis, J.P. A. (2015), “Head-to-Head Randomized Trials Are Mostly Industry Sponsored and Almost Always Favor the Industry Sponsor,” Journal of Clinical Epidemiology, 68, 811–820.
   Google Scholar
• Fleming, T.R. (2008), “Current Issues in Non-Inferiority Trials,” Statistics in Medicine 27, 317–32.
   Google Scholar
• Gao, P., and Ware, J.H. (2008), “Assessing Non-Inferiority: A Combination Approach,” Statistics in Medicine, 27, 392–406.
   Google Scholar
• Gehan, E.A. (1984), “The Evaluation of Therapies: Historical Control Studies,” Statistics in Medicine, 3, 315–324.
   Google Scholar
• Hamasaki, T., and Evans, S.R. (2013), “Noninferiority Clinical Trials: Issues in Design, Monitoring, Analyses, and Reporting,” Igaku no Ayumi, 244, 1212–1216.
   Google Scholar
• Hartzell, J.D., Neff, R., Ake, J., Howard, R., Olson, S., Paolino, K., Vishnepolsky, M., Weintrob, A., and Wortmann, G. (2009), “Nephrotoxicity Associated with Intravenous Colistin (Colistimethate Sodium) Treatment at a Tertiary Care Medical Center,” Clinical Infectious Diseases, 48, 1724–1728.
   Google Scholar
• International Conference on Harmonization (ICH)-E10 (2000), “Choice of Control Group and Related Issues in Clinical Trials,” available at http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E10/Step4/E10_Guideline.pdf.
   Google Scholar
• Koch-Weser, J.K., Sidel, V. W., Federman, E. B., Kanarek, P., Finer, D. C., and Eaton, A. E. (1970), “Adverse Effects of Sodium Colistimethate: Manifestations and Specific Reaction Rates During 317 Courses of Therapy,” Annals of Internal Medicine, 72, 857–868.
   Google Scholar
• Krause, R.M. (1981), The Restless Tide: The Persistent Challenge of the Microbial World, Washington, DC: The National Foundation for Infectious Diseases.
   Google Scholar
• Lee, M., Lee, J., Carroll, M.W., Choi, H., Min, S., Song, T., Via, L., Goldfeder, L., Kang, F., Jin, B., Park, H., Kwak, H., Kim, H., Jeon, S., Jeong, I, Joh, J., Chen, R., Olivier, K., Shaw, P., Follmann, D.A., Song, S., Lee, J.K., Lee, D., Kim, C., Dartois, V., Park, S., Cho, S., and Barry, C. (2012), “Linezolid for the Treatment of Chronic Extensively Drug-Resistant Tuberculosis,” New England Journal of Medicine, 367, 1508–1518.
   Google Scholar
• Li, Y., He, Y., Sheng, Y., Wang, K., Wang, J., Huang, J., Yang, J., and Zheng, Q. (2013), “Systematic Evaluation of Non-Inferiority and Equivalence Randomized Trials of Anti-Infective Drugs,” Expert Review AntiInfectios Therapy, 11, 1377–89.
   Google Scholar
• Molina, J., and Cisneros, J.M. (2015), “A Chance to Change the Paradigm of Outcome Assessment of Antimicrobial Stewardship Programs,” CID, 61, 807–808.
   Google Scholar
• Neaton, J., Gray, G., Zuckerman, B. D., and Konstam, M. A. (2005), “Key Issues in End Point Selection for Heart Failure Trials: Composite Endpoints,” Journal of Cardiac Failure, 11, 567–575.
   Google Scholar
• Paul, M., Bishara, J., Levcovich, A., Chowers, M., Goldberg, E., Singer, P., Lev, S., Leon, P., Raskin, M., Yahav, D., and Leibovici, L. (2010), “Effectiveness and Safety of Colistin: Prospective Comparative Cohort Study,” Journal of Antimicrobial Chemotherapy, 65, 1019–1027.
   Google Scholar
• Powers, J.H. (2008). “Noninferiority and Equivalence Trials: Deciphering ‘Similarity’ of Medical Interventions,” Statistics in Medicine, 27, 343–52.
   Google Scholar
• Powers, J.H., Cooper, C.K., Lin, D., and Ross, D.B. (2005), “Sample Size and the Ethics of Non-Inferiority Trials,” Lancet, 366, 24–5.
   Google Scholar
• Rosenberger, L. H., Lapper, D. J., and Sawyer, R. G.2012 “Infections Caused by Multidrug Resistant Organisms are Not Associated with Overall, All-Cause Mortality in the Surgical Intensive Care Unit: The 20,000 Foot View,” Journal of the American College of Surgeons, 214, 747--755.
   Google Scholar
• Sacks, H., Chalmers, T. C., and Smith, H.1982 “Randomized versus Historical Controls for Clinical Trials,” The American Journal of Medicine, 72, 233--240.
   Google Scholar
• Snappin, S.M. (2000), “Noninferiority Trials,” Current Controlled Trials in Cardiovascular Medicine, 1, 19–21.
   Google Scholar
• Sozu, T, Sugimoto, T., Hamasaki, T., and Evans, S.R. (2015), Sample Size Determination in Clinical Trials with Multiple Endpoints, New York: Springer.
   Google Scholar
• United States Government Accountability Office (2010), Report to Congressional Requesters. New Drug Approval: FDA's Consideration of Evidence from Certain Clinical Trials, . available at http://www.gao.gov/assets/310/308301.pdf.
   Google Scholar
• Wolinsky, E., and Hines, J.D. (1962), “Neurotoxic and Nephrotoxic Effects of Colistin in Patients with Renal Disease,” The New England Journal of Medicine, 266, 759–762.
   Google Scholar